CD8A and neoplasm: Therefore, it is becoming increasingly clear that the combination of ICIs with therapeutic cancer vaccines that aimed at priming or enhancing anti-tumor CD8+ T-cell effectors could increase the efficacy of each treatment used separately [10–12].